Patents by Inventor Marie-Luise Hagmann

Marie-Luise Hagmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASC as a marker for lung cancer
    Patent number: 10175241
    Abstract: The present invention relates to the assessment of lung cancer. It discloses the use of protein ASC in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: January 8, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Marie-Luise Hagmann, Johann Karl, Markus Roessler, Michael Tacke
  • USE OF PROTEIN S100A12 AS A MARKER FOR COLORECTAL CANCER
    Publication number: 20170115294
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Application
    Filed: January 6, 2017
    Publication date: April 27, 2017
    Inventors: Norbert Wild, Ursula Garczarek, Andrea Geistanger, Herbert Andres, Marie-Luise Hagmann, Johann Karl, Freidemann Krause, Michael Pfeffer, Wolfgang Rollinger, Michael Tacke, Michael Thierolf
  • Secernin-1 as a marker for cancer
    Patent number: 9518990
    Abstract: Disclosed is a method aiding in the assessment of cancer. It involves the use of the secernin-1 protein (SCRN1) as a universal marker of different cancer types. More specifically disclosed is a method for assessing cancer from a liquid sample derived from an individual by measuring SCRN1 in the sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: December 13, 2016
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Norbert Wild, Marie-Luise Hagmann, Johann Karl, Julia Riedlinger, Markus Roessler, Michael Tacke
  • FLAP ENDONUCLEASE-1 AS A MARKER FOR CANCER
    Publication number: 20160169895
    Abstract: Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 16, 2016
    Inventors: Norbert Wild, Marie-Luise Hagmann, Johann Karl, Julia Riedlinger, Markus Roessler, Michael Tacke
  • USE OF PROTEIN S100A12 AS A MARKER FOR COLORECTAL CANCER
    Publication number: 20150192587
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Application
    Filed: August 20, 2014
    Publication date: July 9, 2015
    Inventors: Norbert Wild, Ursula Garczarek, Andrea Geistanger, Herbert Andres, Marie-Luise Hagmann, Johann Karl, Friedemann Krause, Michael Pfeffer, Wolfgang Rollinger, Michael Tacke, Michael Thierolf
  • FLAP ENDONUCLEASE-1 AS A MARKER FOR CANCER
    Publication number: 20150072355
    Abstract: Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal.
    Type: Application
    Filed: October 31, 2014
    Publication date: March 12, 2015
    Inventors: Norbert Wild, Marie-Luise Hagmann, Johann Karl, Julia Riedlinger, Markus Roessler, Michael Tacke
  • APEX1 AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    Publication number: 20130344505
    Abstract: An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein APEX1 in said sample in vitro.
    Type: Application
    Filed: September 10, 2013
    Publication date: December 26, 2013
    Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
    Inventors: Marie-Luise Hagmann, Johann Karl, Julia Riedlinger
  • Flap Endonuclease-1 As A Marker For Cancer
    Publication number: 20120157335
    Abstract: Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal.
    Type: Application
    Filed: January 17, 2012
    Publication date: June 21, 2012
    Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
    Inventors: Norbert Wild, Marie-Luise Hagmann, Johann Karl, Julia Riedlinger, Markus Roessler, Michael Tacke
  • SECERNIN-1 AS A MARKER FOR CANCER
    Publication number: 20120028835
    Abstract: Disclosed is a method aiding in the assessment of cancer. It involves the use of the secernin-1 protein (SCRN1) as a universal marker of different cancer types. More specifically disclosed is a method for assessing cancer from a liquid sample derived from an individual by measuring SCRN1 in the sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
    Type: Application
    Filed: October 13, 2011
    Publication date: February 2, 2012
    Inventors: Norbert Wild, Marie-Luise Hagmann, Johann Karl, Julia Kloeckner, Markus Roessler, Michael Tacke
  • PACAP AS A MARKER FOR CANCER
    Publication number: 20110212464
    Abstract: The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the proapoptotic caspase adaptor protein (=PACAP) as a universal marker of different types of cancer. PACAP aids in the assessment of pulmonary or lung cancer (LC), particularly of non-small cell lung carcinoma (NSCLC), but also of other specific types of cancer. Such specific types of cancer are e.g. colon, bladder, cervix, ovary, endometrial, head and neck, breast, melanoma, pancreas, kidney, prostate, esophagus, stomach or bile duct cancer. Furthermore, the present invention especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring PACAP in said sample. Measurement of PACAP can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
    Type: Application
    Filed: May 3, 2011
    Publication date: September 1, 2011
    Inventors: Marie-Luise Hagmann, Johann Karl, Julia Kloeckner, Markus Roessler, Michael Tacke
  • ASC AS A MARKER FOR LUNG CANCER
    Publication number: 20110171676
    Abstract: The present invention relates to the assessment of lung cancer. It discloses the use of protein ASC in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
    Type: Application
    Filed: December 15, 2010
    Publication date: July 14, 2011
    Inventors: Herbert Andres, Marie-Luise Hagmann, Johann Karl, Markus Roessler, Michael Tacke
  • APEX AS A MARKER FOR LUNG CANCER
    Publication number: 20110097756
    Abstract: The present invention relates to the assessment of lung cancer. It discloses the use of protein AP endonuclease (APEX) in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample derived from an individual by measuring APEX in the sample. Measurement of APEX can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
    Type: Application
    Filed: September 10, 2009
    Publication date: April 28, 2011
    Inventors: Marie-Luise Hagmann, Johann Karl, Julia Kloeckner, Markus Roessler, Michael Tacke, Michael Thierolf
  • ASC as a marker for colorectal cancer
    Patent number: 7846653
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein ASC (apoptosis-associated speck-like protein containing a caspase-associated recruitment domain) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring ASC in said sample. Measurement of ASC can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: December 7, 2010
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Marie-Luise Hagmann, Johann Karl, Ursula Kunert, Gabriele Pestlin
  • Measurement of nicotinamde N-methyl transferase in diagnosis of lung cancer
    Patent number: 7785821
    Abstract: The present invention relates to the assessment of lung cancer. It discloses the use of protein NNMT in the assessment of lung cancer. It also relates to a method for assessing lung cancer by measuring NNMT in vitro in a liquid sample derived from an individual. Measurement of NNMT can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: August 31, 2010
    Assignee: Roche Diagnostics Operations Inc.
    Inventors: Wolfgang Rollinger, Marie Luise Hagmann, Johann Karl, Theresa Kott, Markus Roessler, Michael Tacke
  • USE OF PROTEIN S100A12 AS A MARKER FOR COLORECTAL CANCER
    Publication number: 20090286328
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Application
    Filed: November 4, 2008
    Publication date: November 19, 2009
    Inventors: Norbert Wild, Herbert Andres, Ursula Garczarek, Andrea Geistanger, Marie-Luise Hagmann, Johan Karl, Freidemann Krause, Michael Pfeffer, Wolfgang Rollinger, Michael Tacke, Michael Thiefolf
  • USE OF NNMT AS A MARKER FOR LUNG CANCER
    Publication number: 20090263841
    Abstract: The present invention relates to the assessment of lung cancer. It discloses the use of protein NNMT in the assessment of lung cancer. It also relates to a method for assessing lung cancer by measuring NNMT in vitro in a liquid sample derived from an individual. Measurement of NNMT can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
    Type: Application
    Filed: January 30, 2009
    Publication date: October 22, 2009
    Inventors: Wolfgang Rollinger, Marie_Luise Hagmann, Johann Karl, Theresa Kott, Markus Roessler, Michael Tacke
  • Cellular retinoic acid binding protein II as a marker for breast cancer
    Patent number: 7579158
    Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein cellular retinoic acid binding protein II in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring cellular retinoic acid binding protein II in said sample. Measurement of cellular retinoic acid binding protein II can, e.g., be used in the early detection or diagnosis of breast cancer.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: August 25, 2009
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Gabriele Pestlin, Herbert Andres, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Werner Zolg
  • Use of protein ASC as a marker for breast cancer
    Patent number: 7566542
    Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein ASC in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or diagnosis of breast cancer.
    Type: Grant
    Filed: April 14, 2006
    Date of Patent: July 28, 2009
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Gabriele Pestlin, Herbert Andres, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Werner Zolg
  • ASC as a marker for colorectal cancer
    Publication number: 20090155820
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein ASC (apoptosis-associated speck-like protein containing a caspase-associated recruitment domain) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring ASC in said sample. Measurement of ASC can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Application
    Filed: June 20, 2007
    Publication date: June 18, 2009
    Inventors: Herbert Andres, Marie-Luise Hagmann, Johann Karl, Ursula Kunert, Gabriele Pestlin
  • Use of protein PSA3 as a marker for colorectal cancer
    Publication number: 20070218510
    Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein proteasome subunit alpha 3 (PSA3) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring PSA3 in said sample. Measurement of PSA3 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
    Type: Application
    Filed: February 7, 2006
    Publication date: September 20, 2007
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Tacke, Peter Berndt, Marie-Luise Hagmann, Johann Karl, Hanno Langen, Stefan Palme, Markus Roessler, Wolfgang Rollinger, Werner Zolg